Trump Administration Executive Actions and Policy Shifts Impacting LGBTQ+ Health and Care Access A Comprehensive Review

The second administration of President Donald J. Trump has moved with unprecedented speed to overhaul federal policies concerning LGBTQ+ health and social services. Beginning on the first day of his second term, the administration issued a series of executive orders, memoranda, and agency-level directives aimed at dismantling the equity-focused infrastructure established under the Biden administration. These actions represent a fundamental shift in the federal government’s approach to gender identity, civil rights protections, and the provision of medical care for transgender individuals. By redefining biological sex as an immutable binary and restricting federal funding for gender-affirming care, the administration has initiated a transformative—and highly litigated—new era for the U.S. healthcare system.

The Redefinition of Biological Sex and Federal Operations

At the core of the administration’s policy shift is the executive order titled Defending Women From Gender Ideology Extremism and Restoring Biological Truth to the Federal Government. This directive establishes a government-wide policy that recognizes sex as an immutable biological classification of either male or female, determined by reproductive potential. The order explicitly rejects the concept of "gender identity" as a replacement for biological sex in federal law and agency operations.

The implications of this order are extensive. It directs all federal agencies to remove policies, forms, and communications that "promote gender ideology." Agencies are instructed to use the term "sex" instead of "gender" and to cease the collection of gender identity data in many federal surveys. This has already resulted in the removal of sexual orientation and gender identity (SOGI) questions from various federal data collection tools, a move that public health experts warn will make it significantly harder to track health disparities and outcomes within the LGBTQ+ community.

Furthermore, the order directs the Department of Health and Human Services (HHS) to reinterpret Section 1557 of the Affordable Care Act. Under the previous administration, Section 1557 was interpreted to prohibit discrimination based on sexual orientation and gender identity. The Trump administration’s new stance seeks to limit these protections strictly to biological sex, potentially allowing healthcare providers and insurers to deny care or coverage based on a patient’s gender identity without violating federal nondiscrimination statutes.

Restricting Pediatric Gender-Affirming Care

A primary focus of the administration’s health agenda has been the elimination of gender-affirming medical care for minors. The executive order Protecting Children from Chemical and Surgical Mutilation characterizes gender-affirming surgeries and hormonal treatments for those under age 19 as "child abuse." The order directs agencies to take "all appropriate steps" to ensure that federal funds—including research grants and education funding—are not used to support such treatments.

The administration’s efforts to curb these medical practices include several specific mechanisms:

• CMS and Medicaid: The Centers for Medicare and Medicaid Services (CMS) issued a memorandum to state Medicaid agencies suggesting that federal funding for gender-affirming care for minors may violate federal law. A subsequent proposed rule seeks to officially prohibit the use of federal Medicaid and CHIP funds for puberty blockers, hormone therapy, and surgeries for minors.
• Provider Oversight: HHS Secretary Robert F. Kennedy Jr. issued a declaration stating that gender-affirming care for minors does not meet "professionally recognized standards of health care." This declaration provides a framework for the Secretary to potentially exclude providers who offer such care from participating in federal health programs like Medicare.
• Hospital Requirements: A proposed rule would amend the Conditions of Participation for hospitals, requiring those that receive federal payments to stop providing gender-affirming medical interventions to minors. Because nearly all U.S. hospitals accept Medicare or Medicaid, this would effectively create a nationwide ban on hospital-based gender-affirming care for youth.

Dismantling DEI and Health Equity Programs

Parallel to the specific focus on transgender health is a broader campaign to eliminate Diversity, Equity, and Inclusion (DEI) initiatives across the federal government. Through the executive order Ending Radical and Wasteful DEI Programs and Preferencing, the administration has directed agency heads to terminate DEI offices and "equity action plans."

In the context of healthcare, these actions threaten programs designed to reach marginalized populations. The administration has argued that health equity initiatives prioritize "group identity over individual merit." Consequently, federal health agencies like the CDC have updated their mission statements to deprioritize health equity and instead focus on "objective biology." Critics of this shift argue that ignoring social determinants of health and the specific needs of LGBTQ+ populations will exacerbate existing disparities in areas such as mental health, suicide prevention, and HIV/AIDS treatment.

Changes to HIV/AIDS and Veterans’ Health Services

The administration has also targeted specific health programs that have historically provided support for LGBTQ+ individuals. The Ryan White HIV/AIDS Program, which serves over half a million people living with HIV in the U.S., has seen a reversal of policy regarding gender-affirming care. A new HRSA directive prohibits the use of Ryan White funds for hormonal treatments, arguing that these funds should be "marshaled exclusively toward interventions proven to combat HIV." Public health advocates note that for many transgender people living with HIV, gender-affirming care is a critical component of "whole-person care" that improves adherence to antiretroviral therapy.

Similarly, the Department of Veterans Affairs (VA) announced it would phase out gender-affirming care for veterans. While exceptions remain for those already receiving hormone therapy or those transitioning from active military service, the VA will no longer provide new gender-affirming medical services. This represents a significant rollback of the Veterans Health Administration Directive 1341, which had sought to expand access to comprehensive care for transgender veterans.

The Role of the Department of Justice and Regulatory Agencies

The Department of Justice (DOJ) has played a pivotal role in enforcing the administration’s agenda. In a notable legal shift, the DOJ notified the Supreme Court that it no longer supports the challenge to Tennessee’s ban on gender-affirming care for minors, a case originally brought by the Biden administration. Furthermore, an internal DOJ memorandum instructed federal prosecutors to prioritize investigations into medical providers who "mislead the public" about the effects of gender-affirming care, specifically linking these treatments to laws against female genital mutilation.

Other regulatory bodies have also been mobilized:

• The FTC: The Federal Trade Commission issued a request for public comment on "deceptive or unfair practices" related to the marketing of gender-affirming care, suggesting that providers may be failing to disclose material risks.
• The FDA: The Food and Drug Administration issued warning letters to retailers of chest binders, classifying them as "misbranded" medical devices and threatening seizures or injunctions if they are marketed for the treatment of gender dysphoria without registration.

Chronology of Major Actions in 2025

• January 20-28: Issuance of primary executive orders redefining sex, restricting DEI, and targeting pediatric gender-affirming care.
• January 31: OPM and FEHB issue letters to carriers to exclude GAC coverage for the 2026 plan year.
• February 4: First major lawsuits filed (e.g., PFLAG v. Trump) challenging the constitutionality of the executive orders.
• February 11-13: Federal judges issue temporary restraining orders (TROs) in D.C. and Maryland, pausing parts of the "biological truth" and GAC-related orders.
• March 17: VA announces the phase-out of gender-affirming care for veterans.
• April 11: HHS issues a notice clarifying the non-enforceability of gender dysphoria as a disability under Section 504.
• May 28: HHS issues a formal evidence review and letter to providers urging a move away from WPATH standards toward "exploratory therapy."
• June 9: A preliminary injunction is issued in SFAF v. Trump, blocking key provisions of the DEI and gender ideology orders.

Judicial Response and Ongoing Litigation

The administration’s rapid-fire policy changes have met immediate resistance in the federal courts. As of mid-2025, several key components of the executive orders are under preliminary injunctions.

• The "Chilling Effect" Injunctions: Courts in Maryland and Washington have prevented the federal government from withholding or conditioning funding for hospitals that continue to provide gender-affirming care, ruling that the executive orders may violate the Administrative Procedure Act and the Spending Clause of the Constitution.
• Data Restoration: A federal judge in the District of Columbia ordered the administration to restore webpages and datasets related to LGBTQ+ health that had been removed shortly after the inauguration, citing the "irreparable harm" caused by the loss of medical resources.
• First Amendment Protections: In Massachusetts, a court granted an injunction protecting the rights of researchers and physicians whose articles were censored from federal online databases because they contained references to transgender patients.

Broader Impact and Public Health Analysis

The administration’s policies are expected to have a profound impact on the landscape of American healthcare. By moving to exclude gender-affirming care from "Essential Health Benefits" (EHB) for the 2026 plan year, the administration is shifting the financial burden of this care entirely onto patients and states. This will likely lead to a fragmented system where access to care is determined by geography and socioeconomic status.

From a public health perspective, the removal of SOGI data from federal surveys creates a "data vacuum." Without accurate information on the LGBTQ+ community, federal agencies will struggle to respond to public health crises—such as outbreaks that disproportionately affect the community—or to allocate resources for mental health and suicide prevention.

Furthermore, the administration’s promotion of "exploratory therapy"—a term critics say is a euphemism for conversion therapy—conflicts with the consensus of major medical organizations like the American Academy of Pediatrics and the American Psychological Association. These organizations have warned that such shifts could lead to increased rates of depression, anxiety, and self-harm among transgender and gender-nonconforming youth.

As the legal battles continue to unfold, the healthcare industry remains in a state of uncertainty. Providers are caught between conflicting state and federal mandates, while patients face increasing barriers to care that was previously deemed medically necessary. The ultimate resolution of these issues will likely rest with the Supreme Court, which is expected to rule on the constitutionality of state-level bans and federal redefinitions of sex in the coming terms.